SYS-CON MEDIA Authors: Kevin Benedict, Jason Bloomberg, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Heptares Presentation at Future Leaders in the Biotech Industry to be Webcast

LONDON and BOSTON, March 26, 2014 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by its Chief Executive Officer, Malcolm Weir, at BioCentury Future Leaders in the Biotech Industry on 28 March 2014 will be webcast live. The presentation will take place at 9.30am ET in room 302/303 at the Millennium Broadway Hotel & Conference Center, New York City, NY, USA. The webcast will be available from this time at http://www.heptares.com/downloads.

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About  Heptares  Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES  is  a  registered  trademark  in  the  EU,  Switzerland,  US  and  Japan; 

StaR  is  a  registered  trademark  in  the  EU  and  Japan.

SOURCE Heptares Therapeutics

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.